MADRE PELLETIER: UMA INTERLOCUÇÃO ATRAVÉS DA TEIA DO ACESSO À JUSTIÇA ENTRE A UNIVERSIDADE E A COMUNIDADE

CENTRO UNIVERSITÁRIO RITTER DOS REIS - UNIRITTE

Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients

Introduction: The aim of this retrospective proof-of-concept study was to compare different second-line treatments for patients with hepatocellular carcinoma and progressive disease (PD) after first-line lenvatinib or atezolizumab plus bevacizumab.Materials and methods: A total of 1381 patients had PD at first-line therapy. 917 patients received lenvatinib as first-line treatment, and 464 patients atezolizumab plus bevacizumab as first-line.Results: 49.6% of PD patients received a second-line therapy without any statistical difference in overall survival (OS) between lenvatinib (20.6 months) and atezolizumab plus bev-acizumab first-line (15.7 months; p = 0.12; hazard ratio [HR] = 0.80). After lenvatinib first-line, there wasn't any statistical difference between second-line therapy subgroups (p = 0.27; sorafenib HR: 1; immunotherapy HR: 0.69; other therapies HR: 0.85). Patients who under-went trans-arterial chemo-embolization (TACE) had a significative longer OS than patients who received sorafenib (24.7 versus 15.8 months, p < 0.01; HR = 0.64). After atezolizumab plus bevacizumab first-line, there was a statistical difference between second-line therapy subgroups (p < 0.01; sorafenib HR: 1; lenvatinib HR: 0.50; cabozantinib HR: 1.29; other therapies HR: 0.54). Patients who received lenvatinib (17.0 months) and those who under-went TACE (15.9 months) had a significative longer OS than patients treated with sorafenib (14.2 months; respectively, p = 0.01; HR = 0.45, and p < 0.05; HR = 0.46).Conclusion: Approximately half of patients receiving first-line lenvatinib or atezolizumab plus bevacizumab access second-line treatment. Our data suggest that in patients progressed to atezolizumab plus bevacizumab, the systemic therapy able to achieve the longest survival is lenvatinib, while in patients progressed to lenvatinib, the systemic therapy able to achieve the longest survival is immunotherapy

Fibrose pulmonar induzida por bleomicina intraqueal em ratos : uso do interferon-a-2b em um modelo experimental de síndrome da distrição respiratória aguda -SDRA-

Resumo não disponíve

Fibrose pulmonar induzida por bleomicina intraqueal em ratos : uso do interferon-a-2b em um modelo experimental de síndrome da distrição respiratória aguda -SDRA-

Resumo não disponíve

Advances in penile cancer management.

Penile cancer is a rare disease that may cause devastating physical and psychological effects on patients due to the disease itself and/or the associated treatments. As with many other cancer types, significant efforts have been made in penile cancer to minimize invasiveness and morbidity of therapeutic approaches, while aiming to conserve organ function and optimize disease control. This updated review focuses on penile cancer management data published in the last few years.Journal ArticleReviewSCOPUS: re.jinfo:eu-repo/semantics/publishe

Bevacizumab and breast cancer: A meta-analysis of first-line phase III studies and a critical reappraisal of available evidence

BACKGROUND: Randomized studies have shown different magnitude of bevacizumab benefit in the treatment of advanced breast cancer. Regulatory agencies have modified bevacizumab treatment indications across different regions. In this study, we perform a meta-analysis of phase III studies aiming to interrogate the magnitude of bevacizumab benefit for the treatment of first-line HER2-negative metastatic breast cancer (MBC). METHODS: Data from studies E2100, AVADO and RIBBON-1 were used to calculate the benefit of bevacizumab in terms of tumor overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and toxicities. Combined statistical estimates of hazard ratios (HR) and odds ratios were calculated using fixed-effects or random-effects models. RESULTS: A total of 2,695 patients were evaluated. Combining bevacizumab with different chemotherapy backbones resulted in a 30% risk reduction of PFS events (HR = 0.70; 95% confidence interval [CI], 0.57-0.86) and increased ORR (odds ratio 1.81; 95% CI, 1.53-2.14). No OS benefit could be demonstrated (HR = 0.95; 95% CI, 0.85-1.06). Bevacizumab significantly increased the incidence of adverse events such as proteinuria, hypertension and cardiovascular events. CONCLUSIONS: Bevacizumab combined with chemotherapy in the first-line treatment of MBC significantly improved ORR and PFS, but also increased grade 3-4 toxicities. No significant OS advantage was observed

MADRE PELLETIER: UMA INTERLOCUÇÃO ATRAVÉS DA TEIA DO ACESSO À JUSTIÇA ENTRE A UNIVERSIDADE E A COMUNIDADE

CENTRO UNIVERSITÁRIO RITTER DOS REIS - UNIRITTE